Trials of Roche's Perjeta show it could help extend the lives of women with advanced breast cancer by over a year compared to existing treatments. The results from the CLEOPATRA study are a ...
The European Union’s Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion to Roche’s Perjeta (pertuzumab) for use in combination with herceptin (trastuzumab ...
Kadcyla and Perjeta, the new class of drugs launched in India in October, cost Rs 2,10,000 (200 ml) and Rs 2,49,000 for a dosage, respectively. ET verified the price with several chemists and ...